These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29340073)

  • 1. YM155 exerts potent cytotoxic activity against quiescent (G
    Ookura M; Fujii T; Yagi H; Ogawa T; Kishi S; Hosono N; Shigemi H; Yamauchi T; Ueda T; Yoshida A
    Oncotarget; 2017 Dec; 8(67):111535-111550. PubMed ID: 29340073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
    Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A; Ookura M; Zokumasu K; Ueda T
    Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
    Miyamoto R; Kurita S; Tani H; Ikeda T; Ishizaka M; Saima H; Kobayashi M; Tamura K; Bonkobara M
    Vet J; 2018 Oct; 240():31-36. PubMed ID: 30268330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.
    Zhang Y; Zhou L; Leng Y; Dai Y; Orlowski RZ; Grant S
    Oncotarget; 2017 Aug; 8(35):59476-59491. PubMed ID: 28938651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells.
    Zhang C; Cao X; Gei Y; Wang Y; Liu G; Cheng G; Liu Q
    Oncol Lett; 2015 Sep; 10(3):1627-1631. PubMed ID: 26622722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.
    Cheng Q; Ling X; Haller A; Nakahara T; Yamanaka K; Kita A; Koutoku H; Takeuchi M; Brattain MG; Li F
    Int J Biochem Mol Biol; 2012; 3(2):179-97. PubMed ID: 22773958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
    Kim HJ; Kim SM; Park KR; Jang HJ; Na YS; Ahn KS; Kim SH; Ahn KS
    Cancer Lett; 2011 Feb; 301(1):29-37. PubMed ID: 21122982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YM155 enhances docetaxel efficacy in ovarian cancer.
    Hou LJ; Huang XX; Xu LN; Zhang YY; Zhao N; Ou RY; Li WF; Zhang WJ; Jiang QW; Yang Y; Wei MN; Huang JR; Wang K; Yuan ML; Xing ZH; Shi Z; Yan XJ
    Am J Transl Res; 2018; 10(3):696-708. PubMed ID: 29636860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.
    Zhang Z; Zhang Y; Lv J; Wang J
    Int J Clin Exp Med; 2015; 8(10):18032-40. PubMed ID: 26770398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
    Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
    Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells.
    Wani TH; Surendran S; Mishra VS; Chaturvedi J; Chowdhury G; Chakrabarty A
    Oncotarget; 2018 Sep; 9(71):33589-33600. PubMed ID: 30323901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of BOR-Resistant U266 Cell Line and the Detection of Its Biological Activities].
    Liu HL; Que WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1722-1726. PubMed ID: 29262905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.